HF
RNTX

HRT Financial’s Rein Therapeutics RNTX Stock Holding History

HRT Financial’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Sell
15,486
-17,751
-53% -$22K ﹤0.01% 3577
2025
Q4 		$38K Buy
+33,237
New +$45.8K ﹤0.01% 2914
2023
Q2 		– Sell
-11,671
Closed -$14K – 3432
2023
Q1 		$14K Buy
+11,671
New +$25K ﹤0.01% 2222
2022
Q1 		– Sell
-532
Closed -$5K – 4018
2021
Q4 		$5K Sell
532
-433
-45% -$6.7K ﹤0.01% 3053
2021
Q3 		$19K Buy
+965
New +$21.1K ﹤0.01% 3146

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

HRT Financial's RNTX Position: Q1 2026 in Review

HRT Financial reduced its Rein Therapeutics (RNTX) stake by 53% in Q1 2026, selling an estimated $22K and leaving 15,486 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #3577.

HRT Financial first reported a position in RNTX in Q3 2021 and has held it in 5 quarters since. The position peaked at $38K in Q4 2025. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • HRT Financial held 15,486 shares of Rein Therapeutics worth $20K as of Q1 2026.
  • HRT Financial sold 17,751 Rein Therapeutics shares in Q1 2026, an estimated $22K.
  • Rein Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3577 holding.
  • HRT Financial first reported a position in Rein Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • HRT Financial's Rein Therapeutics position peaked at $38K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.